212 related articles for article (PubMed ID: 15554339)
1. Industry probe. Justice Department subpoenas dialysis providers.
Mantone J
Mod Healthc; 2004 Nov; 34(44):17. PubMed ID: 15554339
[No Abstract] [Full Text] [Related]
2. Whopping settlement for Fresenius.
Taylor M
Mod Healthc; 2000 Jan; 30(4):6. PubMed ID: 11009992
[No Abstract] [Full Text] [Related]
3. Overview 2012. A year of dialysis industry alignment and government enforcement.
Riley JB; Greis JS
Nephrol News Issues; 2013 Mar; 27(3):37-8. PubMed ID: 23581175
[TBL] [Abstract][Full Text] [Related]
4. Proposed conditions for coverage directed toward dialysis facilities.
Smetanka S
Health Care Law Mon; 2005 Apr; ():3-11. PubMed ID: 15895752
[No Abstract] [Full Text] [Related]
5. Economic corrections and the potential impact on the dialysis industry.
Sullivan JD
Nephrol News Issues; 2009 Jul; 23(8):14-6. PubMed ID: 19662907
[No Abstract] [Full Text] [Related]
6. A discussion of pharmaceutical industry practices viewed as illegal by the federal government.
Nino K
Health Care Law Mon; 1999 Nov; ():8-16. PubMed ID: 11067433
[No Abstract] [Full Text] [Related]
7. Using knowledge of multiple levels of variation in care to target performance incentives to providers.
Turenne MN; Hirth RA; Pan Q; Wolfe RA; Messana JM; Wheeler JR
Med Care; 2008 Feb; 46(2):120-6. PubMed ID: 18219239
[TBL] [Abstract][Full Text] [Related]
8. Have you looked at your wage index lately?
Feigal MS; Whalen JE
Nephrol News Issues; 2009 Jul; 23(8):56-8. PubMed ID: 19662911
[No Abstract] [Full Text] [Related]
9. Lessons from expanded government enforcement efforts against drug companies.
Scheineson MJ; Klinger ST
Food Drug Law J; 2005; 60(1):1-16. PubMed ID: 15940851
[No Abstract] [Full Text] [Related]
10. Serratia liquefaciens infections at a hemodialysis center.
Sullivan JD
N Engl J Med; 2001 Sep; 345(12):922; author reply 922-3. PubMed ID: 11565530
[No Abstract] [Full Text] [Related]
11. Comments on proposed conditions for coverage focus on patient care, training, facility upgrades.
Leiby M
Nephrol News Issues; 2005 Aug; 19(9):15-7. PubMed ID: 16173298
[No Abstract] [Full Text] [Related]
12. Collateral damage. Providers face negative fallout from the war on drugmakers.
Taylor M
Mod Healthc; 2001 Jun; 31(24):30-3. PubMed ID: 11430166
[No Abstract] [Full Text] [Related]
13. Pharmaceutical manufacturers likely to be challenged by regulatory agencies over assertions of deceptive advertising.
Fine A
Exec Solut Healthc Manag; 1999 Jun; 2(6):2-3. PubMed ID: 10538255
[No Abstract] [Full Text] [Related]
14. Optimizing 340B purchasing practices.
Almeter PJ; Johnson GL; Saenz R
Am J Health Syst Pharm; 2012 Aug; 69(16):1366-8, 1370-1. PubMed ID: 22855101
[No Abstract] [Full Text] [Related]
15. Why a fluid manager makes sense in your dialysis clinic.
Diroll A
Nephrol News Issues; 2013 Jun; 27(7):10, 12. PubMed ID: 23855139
[No Abstract] [Full Text] [Related]
16. PBMs: ripe for regulation.
Johnson RS
Food Drug Law J; 2002; 57(2):323-69. PubMed ID: 12437004
[No Abstract] [Full Text] [Related]
17. Dialysis providers cope with dwindling payments.
Burns J
Mod Healthc; 1992 May; 22(19):56, 58. PubMed ID: 10117630
[TBL] [Abstract][Full Text] [Related]
18. Enforcement actions involving Medicaid fraud and abuse, 1996-2009.
Qureshi ZP; Liu Y; Sartor O; Chu YH; Bennett CL
Arch Intern Med; 2011 Apr; 171(8):785-7. PubMed ID: 21518950
[No Abstract] [Full Text] [Related]
19. Fresenius agrees to large settlement.
Taylor M
Mod Healthc; 1999 Nov; 29(48):4. PubMed ID: 10662204
[No Abstract] [Full Text] [Related]
20. NN&I's 7th annual survey: the growth game.
Cooper L
Nephrol News Issues; 2001 Jul; 15(8):29-30. PubMed ID: 12099227
[No Abstract] [Full Text] [Related]
[Next] [New Search]
